New Alzheimer's drug slows cognitive decline – and may be available as early as next year
(Version anglaise seulement)
par Bernadette McGuinness, Clinical Professor of Ageing, Queen's University Belfast
Elizabeth Coulthard, Associate Professor in Dementia Neurology, University of Bristol
Lecanemab is the first drug to help improve the symptoms of Alzheimer’s by slowing the disease. These are very promising results, although the only data we have at the moment is from the drugmaker’s press release.
Lecanemab is an antibody that finds and removes a protein called amyloid that builds up and forms clumps in the brains of people with Alzheimer’s disease. By targeting amyloid, lecanemab is striking at the heart of the disease…
Lire l'article complet
© La Conversation
-
mardi 4 octobre 2022
